Themis Medicare

From FAMEPedia, The free encyclopedia
Themis Medicare Limited
FounderShantilal D Patel, KT Lakdawala
Legal statusPublic limited company
HeadquartersMumbai, India
SubsidiariesArtemis Biotech, Themis Medicare Singapore Pte Ltd.
Formerly called
Themis Chemicals

Themis Medicare Limited, headquartered in Mumbai, India, is an Indian pharmaceuticals company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and drug formulations. It also supplies its products to a number of other Indian pharmaceutical companies.[1]

History[edit | edit source]

Themis has its roots in the Mumbai-based Therapeutic Pharmaceuticals, which was co-founded on November 28, 1952, by three pharmacy graduates Shantilal D Patel, Kantibhai and KP Menon. Over the years, it was known by names such as Laboratories Orgasyn, Chemosyn Laboratories, and Themis Chemicals (a joint venture with the Hungarian pharmaceutical company Gedeon Richter).[2]

Themis was incorporated in the year 1969,[3] by Shantilal D Patel and KT Lakdawala.[4] The joint venture was originally promoted by Chemosyn and Medimpex (Hungarian company) before it was taken over by a group consisting of Shantibhai D Patel and K T Lakdawala.[5] In 2004, Themis merged with Artemis Biotech (formerly Andhra Citrates Ltd), which was engaged in manufacturing biotechnology products.[6]

As of 2020, its top management includes Dinesh S Patel, Jayshree D Patel, Vijay Agarwal, Rajneesh Anand, Lajos Kovacs, Humayun Dhanrajgir, Hoshang Sinor, Hariharan Subramaniam, Sachind D Patel, Gabor Gulacsi, Reena S Patel.[7]

Themis is listed on the Bombay Stock Exchange and the National Stock Exchange.[8]

Facilities and product segments[edit | edit source]

Themis has two manufacturing facilities - one located at Vapi and another at Hyderabad.[4]

The company focuses on therapeutic areas, including anti-tuberculosis, anti-malarial, cardiology, pain management, anti-infectives, haematinics, health and nutrition. Its APIs include Simvastatin, Ethambutol, Artemether, Artesunate, Arteether[9] and Di Methyl Isosorbide. Themis's formulations include original products, new drug delivery systems (NDDS), dietary supplements and others. Its original products include Emal injection, Sepgard Gel, Sepgard Mouth Gargle and Sepgard Solution. Other NDDS include Injection Diclofenac Sodium, Gel Diclofenac Diethylamine, Emal Prefilled Injection, Etojet injection and Injection Aceclofenac. Themis also offers a range of dietary supplements.[10]

References[edit | edit source]

  1. "Themis Medicare Share Price, Themis Medicare Stock Price, Themis Medicare Ltd. Stock Price, Share Price, Live BSE/NSE, Themis Medicare Ltd. Bids Offers. Buy/Sell Themis Medicare Ltd. news & tips, & F&O Quotes, NSE/BSE Forecast News and Live Quotes". Retrieved 2020-11-09.
  2. "Dr. Dinesh Patel, Managing Director & CEO, Themis Medicare Ltd". Retrieved 2020-11-11.
  3. "Themis Medicare Ltd Stock Price - (348.95), Themis Medicare Ltd Share Price Live Today, Themis Medicare LtdStock Live BSE/NSE Share Price". Retrieved 2020-11-09.
  4. 4.0 4.1 "History of Themis Medicare Ltd., Company". Goodreturn. Retrieved 2020-11-11.
  5. "Themis Medicare Ltd". Business Standard India. Retrieved 2020-11-11.
  6. "Themis Medicare". Retrieved 2020-11-11.
  7. "Themis Medicare share price live today - Why Themis Medicare share price is up by 3.90% today? Themis Medicare share price analysis | ETMarkets". Retrieved 2020-11-09.
  8. "Themis Medicare Ltd Stock Price - (348.95), Themis Medicare Ltd Share Price Live Today, Themis Medicare LtdStock Live BSE/NSE Share Price". Retrieved 2020-11-09.
  9. Dikshit, Madhu; Dikshit, D. K. (2016). "Drug discovery research in India". Current Science. 111 (2): 252–255. ISSN 0011-3891.
  10. "Company Profile for Themis Medicare Ltd". Retrieved 2020-11-09.
The contents of this page are sourced from Wikipedia. The contents are available under the CC BY-SA 4.0 license.